Reg. CF

Kiddie, Inc.

Offering By Kiddie, Inc.

About Documents
Funded - $15500
Time Left - 36 days
Target - $25,000
Max. Raise - $1,070,000


Project Overview

Kiddie, Inc.

Kiddie, Inc. is a new company, formed in August 2020, entering into the online telemedicine business for the purpose of providing pediatric healthcare, prescriptions and other products.

  • Ready to Launchthe KiddieRX App has already been designed and its technical documentation has already been written.
  • Huge Market Opportunity: pediatric telemedicine is estimated to reach $4.6 billion by 2025, a market share capture of just 3% would lead to $41.1 million in revenue.
  • Experienced Executivesthe founding team combines experience in publicly traded companies and international business management skills.



Bronze Tier
Invest at least $100 and get a free 1 year membership of KiddieRX + 1,000 shares of KiddieRX ($1.00 = 10 shares).


Silver Tier
Invest at least $250 and get a free 1 year membership of KiddieRX + 1 tee by KiddieRX + 2,500 shares of KiddieRX ($1.00 = 10 shares).


Gold Tier
Invest at least $500 and get a free 1 year membership of KiddieRX + 1 tee and hat by KiddieRX + 5,000 shares of KiddieRX ($1.00 = 10 shares).


Platinum Tier
Invest at least $1,000 and get a free 1 year membership of KiddieRX + 1 tee and hat by KiddieRX + exclusive access to the beta version of the app + 10,000 shares of KiddieRX ($1.00 = 10 shares).


Emerald Tier
Invest at least $5,000 and get a free 1 year membership of KiddieRX + 1 tee and hat by KiddieRX + an exclusive invitation to a dinner event with the exectuive team (travel costs to the event/dinner are not included) + 50,000 shares of KiddieRX ($1.00 = 10 shares).


Diamond Tier
Invest at least $10,000 and get all Emerald Tier incentives + 100,000 shares of KiddieRX ($1.00 = 10 shares) + 5% bonus shares (5,000 bonus shares).


Blue Diamond Tier
Invest at least $25,000 and get all Emerald Tier incentives + 250,000 shares of KiddieRX ($1.00 = 10 shares) + 10% bonus shares (25,000 bonus shares).


Black Diamond Tier
Invest at least $50,000 and get all Emerald Tier incentives + 500,000 shares of KiddieRX ($1.00 = 10 shares) + 15% bonus shares (75,000 bonus shares).


The Opportunity

Telemedicine is seeing rapid adoption from practitioners and patients alike, relying on drivers such as accessibility, state of the art technology, ease of use, low overhead costs, and most recently, the need for social distancing spurred by COVID-19. 

Currently, the U.S. telemedicine market stands at USD 10 billion, with a CAGR of 29%, and is expected to reach USD 34 billion by 2025. The rapidly expanding pediatric telemedicine segment is calculated* at USD 1.37 billion today. Based on those calculations and CAGR, pediatric telemedicine would reach an estimated USD 4.6 billion by 2025.

For example, today, a market share capture of just 3% would lead to USD 41.1 million in revenue. In 5 years, growing at the projected CAGR of 29%, that number would increase to USD 139.7 million.

With the healthcare industry reaching maturity with many competitors, investors can focus their efforts on a small niche subsection such as pediatric telemedicine and benefit from a first-mover advantage in order to maximize ROI. 

The Problem 

There is a gap in conventional medicine:

  • up to 30% of RX are never filled 
  • up to 50% of RX are not taken as prescribed

The Problem

The Solution

Our closed-loop KiddieRX medical ecosystem alerts us to unfulfilled prescriptions, sends out push notifications to remind patients, and features a convenient prescription delivery service, resulting in a healthier patient and more prescriptions sold.

The Problem


Project Timeline

Timeline for 2020


Timeline for 2021


To be an end-to-end service provider offering a medical online platform that helps parents resolve the healthcare issues of their children, easily, quickly and economically from the privacy and comfort of their home. No need to drive to, and wait in, a physician’s office, or even go to, or wait, at a pharmacy for your child’s prescriptions.

Our mission is to disrupt the pediatric healthcare industry by providing better and more affordable pediatric care for children and their parents, while consequently achieving the following:

  • Promoting an efficient telemedicine alternative with access to real doctors in real time

  • Guaranteeing prescription medicine is fulfilled, delivered, and taken as prescribed

  • Offering a full range of services at an ultra-competitive price

With the market trending towards on-demand services, KiddieRX is positioned to capture about 3% of the pediatric telemedicine market.

Alberto Prieto
CEO of Kiddie, Inc.

”In a rapidly evolving digital world, the KiddieRx’s platform allows for faster, safer and easier patient care. Moms & Dads can now ease their minds knowing they have a quality pediatrician in their pocket at any time.”

What will we do

Through our dedicated and reliable partnerships, we’re able to expand our reach and offer our users a superior level of care on a nearly nationwide scale, with benefits that surpass those of our competitors.

Our critical drivers:

  1. Cutting Edge Telemedicine Technology. We are committed to making continuous improvements to our app features, staying up-to-date with the technological advancements of the industry to remain ahead of the curve in the telemedicine market
  2. Strong Network of Doctors. We curate a network of qualified and highly recommended pediatric physicians from 48 states, giving our users 24/7 access to a pediatrician when and where they need it most
  3. Strategic Pharmacy Partner. We’ve chosen to partner with a top-grade pharmacy that allows us to provide a wide range of prescription medication at a competitive price and delivered in a timely fashion. Additionally, we can work with users preferred pharmacies.

Onboarding Doctors

We’ve simplified the telemedicine pediatric care experience for pediatricians and pharmacies with access to the nationwide KiddieRX patient network, intuitive UI, interactive chatbot assistance, video conferencing capabilities, efficient 2-4 hour or next-day prescription delivery with Fedex and UPS, and a streamlined process that’s easy for everyone

1. Build Network

Doctors & pharmacies apply to join KiddieRX pediatrician and pharmacy network, thanks to our attractive shareholding model.

2. Vetting Process

The KiddieRX team thoroughly vets all applications, approving only top quality submissions.

3. Network Approval

Once approved, pediatricians and pharmacies become part of the expanding KiddieRX network.

4. Complete EMR Registration

Submit all necessary information to become fully integrated, gaining access to the 24/7, nationwide KiddieRX patient base.

5. Confirm Payment Process

Financial information is completed and confirmed with a test deposit.

KiddieRX Benefits


Traditional Pediatrician & Pharmacy Visit 


KiddieRX Telemedicine Experience

 (15 min) Get sick child out of bed and into car Allow your sick child to rest and recuperate at home
(30 min) Deal with traffic driving to and from doctor’s office Avoid lengthy car rides
(10 min) Check in and fill out paperwork at doctor’s office  Bypass tedious paperwork with the easy-to-use app
(30 min) Wait with other sick children before seeing doctor  Stay safe at home
(15 min) Wait in examination room, then doctor’s visit begins  Visit doctor on your own time while your child rests
(30 min) Deal with traffic driving to and from the pharmacy  Order your prescriptions comfortably from home
(15 min) Wait in line to order the medication  Avoid traffic and lengthy lines at the pharmacy
(15 min) Wait for medication to be prepared  Prescription is delivered straight to your door
(30 min) Return home with sick child and medicine  (30 min) Return home with sick child and medicine
An estimated total time of 3h 10m  

Traditional Visits

KiddieRX Visits

 Pediatricians limited to treating patients in close proximity  Pediatricians can serve patients nationwide
 Available only by appointment & during office hours  Access anywhere, anytime. No appointment needed
❌ Difficult to access your medical history  Easily access your medical history
 Tedious paperwork and medical forms to fill out  Avoid confusing paperwork with our easy-to-use app
 Costs of doctor add up per visit  Unlimited visits and checkups

Traditional Visits to Pharmacy

KiddieRX Telemedicine

 Wasted time driving to the pharmacy  Keep prescriptions filled from the comfort of home
 Lost time waiting for prescriptions to be filled  Avoid waiting in lines for your prescriptions
 Limited or no home delivery options  2-4 hour and overnight home delivery options
 Limited to near-home options  Access across the country
 Poor communication between doctor and pharmacy  Strong doctor-to-pharmacy communication

Pediatric Market

The current rapid expansion of the medical industry presents a large market opportunity as over the next five years, the primary care market size is projected to experience a CAGR of 4.7%, the pediatric care market size a CAGR of 3.7%, and the prescription market size a CAGR of 8.9%.

Market Opportunity for Telemedicine

The telemedicine market is projected to hit $34 billion USD by 2025, growing at an impressive CAGR of 29%, presenting us with a significant market opportunity.

Pediatric Telemedicine Market Analysis

The telemedicine industry continues to see exponential growth with COVID-19 introducing many new adopters to the digital platform. Research shows that the majority have become repeat users due to the app experience, quality of care, facility, and around-the-clock availability.

Supporting Health Industry Statistics

Platform Structure

KiddieRX elevates the pediatric telemedicine experience, giving users 24/7 access to qualified pediatric care from the comfort of their homes through virtual visits and prescription delivery services.

A premium pediatric telemedicine ecosystem, KiddieRX combines a strong network of pediatrics with cutting edge technology and strategic pharmacy partnership to deliver an accessible and complete approach to nationwide pediatric care.

Patient Onboarding

App Download

Patient seeking pediatric care downloads the app on iOS or Android, and registers their account.

Patient Profile

Child’s medical background is submitted through app (1-time setup).

Visit Initiation

Virtual visit begins in a matter of minutes using video chat or text messages

Prescription Submission

If needed, prescriptions can be shipped or filled at preferred pharmacy option.

Feedback Request

User is asked to provide discreet feedback that is then used to optimize process. The patient experience is measured by NPS - Net Promoter Score methodology & standards.

Corporate Onboarding

Corporate Outreach

Sales rep contacts company’s HR department.

Code Creation

After striking a deal, a unique corporate code is created.

Code Distribution

HR shares code with employees.

Employee Registration

Employees register & enter corporate code to receive discount.

User Preferences

Users can set a number of preferences to enjoy a personalized experience.

Easy Onboarding

Smart Chatbot - Interactive chatbot will welcome new users, walking them through every step of the onboarding process.

Faster Onboarding - Users will be ushered through the check-in process and connected quickly with the first available doctor.

Form Filling Made Easy - Our paperless, easy-to-use forms are more intuitive than confusing in-office paperwork.

One Time Registration - Register only once. No need to re-register to see a new pediatrician.


Visit Experience

24/7 Pediatrician Chat
Keep a pediatrician in your pocket and at your fingertips any time, anywhere.


Send Files on the Go
Share images via text with file attachments.


Versatile Virtual Visits
Switch between video conference and text chat to send attachments and written information as needed.

Visit Follow-Up

User Experience Evolution
Users can rate their visit, allowing the team to monitor how well pediatricians are performing to ensure a top-notch quality service.


Access Records Instantly
Once a visit is completed, users can request a copy of their medical documentation through the app.

Security and Privacy

KiddieRX is compliant with all applicable rules and regulations of the Health Insurance Portability and Accountability Act (HIPAA). We are committed to keeping all PHI (Protected Health Information) that our patients entrust to us private and secure. We have instituted policies and procedures to ensure this is done.

iOS / Android Support

The app is developed with compatibility in mind and will be available on iOS & Android with key features like the default biometrics login and payment preferences already set in their systems. This ensures that users can seamlessly enjoy the benefits of KiddieRX no matter their smartphone preferences.

Plans and Costs
Users will receive a free initial visit. After that, they can choose from a subscription plan (best value) or Pay-Per-Visit option.

Corporate Benefits Coverage

Network of Providers - Partnering with insurance companies and offering corporate benefits coverage ensure that KiddieRX continues to expand its growing network of patients and service providers.

Health Insurance Providers - We partner with major health insurance providers such as Aetna and Florida Blue to ensure users have access to their preferred prescription discounts.

Corporate Benefits Coverage - We have a dedicated team working with companies to help them offer KiddieRX as a corporate benefit, so their employees can enjoy the service for free.

Use of Proceeds

We will adjust roles and tasks based on the net proceeds from the offering. We plan to use these proceeds as described below, which amount determinations have been established by management.  All amounts as stated are approximate, and estimated as a +/-20% variance.

Offering Expenses

The use of proceeds for expenses related to the Combined Offering is as follows:

  • If the Company raises the Minimum Offering Amount, it will use 0% of the proceeds, or $0 towards offering expenses;
  • If the Company raises the Maximum Offering Amount, it will use 5.14% of the proceeds, or $55,000 towards offering expenses

The following table lists the use of proceeds of the Offering if the Minimum Amount and Maximum Amount are raised.

Use of Proceeds

% of Minimum Proceeds Raised
("Target Offering Amount")

Amount if Minimum Raised

% of Maximum Proceeds Raised

Amount if Maximum Raised

Intermediary Fees





Application Development and IT related





Marketing expenses and related reimbursement





Estimated Attorney Fees





Estimated Accounting Related Fees





General Working Capital










The above table is not inclusive of fees paid for use of the Form C generation system, payments to financial and legal service providers, and escrow related fees, all of which were incurred in preparation of our services introduction.

The above table of the anticipated use of proceeds is not binding on the Company and is merely a description of its current intentions.  The Company reserve the right to change the above use of proceeds if management believes it is in the best interests of the Company.

Ownership Structure & Rights of Securities


The Company has the following outstanding Securities:

Type of security

Amount outstanding

Voting rights (One vote per share)

Percentage ownership of the Company by the holders of such securities prior to the offering

Other material terms

Common Stock





Preferred Stock







Below are the beneficial owners of 20% percent or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, listed along with the amount they own.


Number and type / class of security held

Percentage ownership (pre-offering)

Supreme Capital Fund, L.P.

55,000,000 shares of common stock


Lifestyle Equities, LLC

5,000,000 shares of common stock


Lifestyle Equities, LLC, is a Florida limited liability company, whose managing member is Lee Lefkowitz, a founder of the Company. Supreme Capital Fund, L.P. is a Nevada limited partnership whose general partner is Supreme Capital Management, LLC, a Wyoming limited liability company.

Risks & Disclosures

Crowdfunding for early-stage companies is relatively new. Crowdfunding (defined as online offerings of the securities of early-stage companies to retail investors) is a relatively new industry that has only started to develop with the SEC’s adoption of Regulation A+ in June 2015 and Regulation Crowdfunding on May 16, 2016. Early-stage companies may be slow to adopt crowdfunding as a method of capital formation, which would mean fewer deals for investors to choose from and less research for us to prepare. Alternatively, investors may be slow to adopt crowdfunding as a viable investment substitute, which would mean fewer early-stage companies raising money and a smaller potential customer base. As a result, a risk exists that we acquire fewer customers or acquire customers at a slower pace than we anticipate.

As a new company we have a limited operating history. The Company was organized on August 2020. It has only recently launched its website, and has no revenues. We have a limited operating history upon which you may evaluate our business and prospects. We are in the early stages of our business and have not yet commenced full-scale operations. Accordingly, we are in the initial revenue phase, and our activities to date have involved business planning, market testing and efforts to raise startup capital. Our business and prospects must be considered in light of the risk, expense and difficulties frequently encountered by pre-revenue companies in early stages of development, particularly companies in highly competitive and evolving markets. If we are unable to effectively allocate our resources, provide our services, generate sales, or obtain and grow our customer base, our business operating results and financial condition would be adversely affected and we may be unable to execute our business plan, and our business could fail. Investors could therefore be at risk of losing their investment. If you are investing in this company, it’s because you believe in the idea and the market opportunity, the quality of the team, and the direction of the business to date.

Our projections are speculative and are based upon a number of assumptions. Any projected financial results prepared by or on behalf of the Company have not been independently reviewed, analyzed, or otherwise passed upon. Such “forward-looking” statements are based on various assumptions, which assumptions may prove to be incorrect. Such assumptions include, but are not limited to (i) the future status of local and regional economies, (ii) anticipated demand for our services, (iii) anticipated costs associated with the development, marketing, sales and distribution of our services, and (iv) anticipated procurement and retention of a customer base. Accordingly, there can be no assurance that such projections, assumptions, and statements will accurately predict future events or actual performance. Any projections of cash flow should be considered speculative and are qualified in their entirety by the assumptions, information and risks disclosed herein. Investors are advised to consult with their own independent tax and business advisors concerning the validity and reasonableness of the factual, accounting and tax assumptions. No representations or warranties whatsoever are made by the Company or any other person or entity as to the future profitability of the Company or the results of making an investment in the Company. If our future projections end up being significantly different than currently projected, our business could be greatly impacted. Our business therefore may not be able to sustain itself without the projected future revenues. The business could be at risk of closing, and investors may therefore be at risk of losing their investments.

We may not effectively manage growth. The anticipated growth of the Company’s business will result in a corresponding growth in the demands on the Company’s management and its operating infrastructure and internal controls. While we are planning for managed growth, any future growth may strain resources and operational, financial, human and management information systems, which may not be adequate to support the Company’s operations and will require the Company to develop further management systems and procedures. There can be no guarantee that the Company will be able to develop such systems or procedures effectively on a timely basis. The failure to do so could have a material adverse effect upon the Company’s business, operating results and financial condition. Investors could therefore be at risk of losing their investments if growth is not managed effectively.

We expect our expenses to grow as the Company grows. Our expenses will increase as we build infrastructure to implement our business plan. For example, we may hire additional employees, expand our product offerings, and lease more space for our corporate offices. This poses a risk to the financial forecasts and current financial model of the Company.

The Company may not reach its sales goals. The Company has forecasted its capitalization requirements based on sales goals and cost containment measures; any reduction to these forecasts could make it difficult for the company to achieve its projected growth, which would affect available cash and working capital, ultimately affecting the Company’s financial condition. This could put the investor at risk of losing their investment.

We expect losses in the foreseeable future. Excluding the effect of any future non-operating gains, we expect to incur losses for the foreseeable future and, if we generate revenues, or have profits, we may not be able to sustain them. Our expenses will increase as we build an infrastructure to implement our business model. For example, we may hire additional employees, expand information technology systems, and lease space for operations. In addition, we plan to significantly increase our operating expenses to fully develop and broaden our technology and acquire customers.

Our success is dependent on our key personnel. We believe that our success will depend on the skill and expertise of our management. If they are unsuccessful in overseeing and growing our operation, our business will be at risk.

We rely on third parties to provide services essential to the success of our business. We rely on third parties to provide a variety of essential business functions for us. It is possible that some of these third parties will fail to perform their services or will perform them in an unacceptable manner. It is possible that we will experience delays, defects, errors, or other problems with their work that will materially impact our operations and we may have little or no recourse to recover damages for these losses. A disruption in these key or other operations could materially and adversely affect our business. As a result, your investment could be adversely impacted by our reliance on third parties and their performance.

We compete with other companies. A number of competitors exist in the telemedicine space. As the market grows, we anticipate more competition and price pressure on our business model which may limit our success.

The Company is vulnerable to hackers and cyberattacks. As an internet-marketed business, we may be vulnerable to hackers or cyberattacks. Further, any significant disruption in service on our website or in its computer systems could reduce the attractiveness of the company and result in a loss of business. Further, we rely on a third-party technology provider to provide some of our back-up technology. Any disruptions of services or cyber-attacks either on our technology provider or on the Company could harm our reputation and materially negatively impact our financial condition and business.

The Company may be unable to maintain, promote, and grow its brand through marketing and communications strategies. It may prove difficult for the Company to dramatically increase the number of customers that it serves or to establish itself as a well-known brand. Additionally, the product may be in a market where customers will not have brand loyalty.

Failure to obtain new customers or renew customer contracts on favorable terms could adversely affect results of operations. The Company may face pricing pressure in obtaining and retaining its customers.

The Company may face challenges maintaining, promoting, and growing its brand through marketing and communications strategies. It may prove difficult for the Company to dramatically increase the number of customers that it serves or to establish itself as a well-known brand in its competitive space. Additionally, the service may be in a market where customers will not have brand loyalty.

The Company projects aggressive growth. If these assumptions are wrong and the projections regarding market penetration are too aggressive, then the financial forecast may overstate the Company's overall viability. In addition, the forward-looking statements are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Failure to adapt to technological changes may render our technology obsolete or decrease the attractiveness of our solutions to our customers. Although we believe our current technology and processes will be suitable for operations well into the foreseeable future, if new industry standards and practices emerge, or if competitors introduce new solutions embodying new services or technologies, our technology and processes may become obsolete. Our future success will depend in part on our ability to fully develop and enhance our technology, develop and potentially license new solutions and technologies that address the needs of our prospective customers; and respond to changes in industry standards and practices on a cost-effective and timely basis.

We must continue to enhance the features and functionality of our technology and service offering. The effective performance, reliability and availability of our technology and service offering are critical to our reputation and our ability to attract and retain customers. If we do not continue to make investments in product development and, as a result, or due to other reasons, fail to attract new and retain existing customers and investors, this could significantly decrease the value of our service to all customers and stakeholders. There can be no assurance that we will be successful in developing, marketing and selling our service to meet changing demands, that we will not experience difficulties that could delay or prevent the successful development, introduction, and marketing of service enhancements, or that any such service enhancements will adequately meet the demands of the marketplace and achieve market acceptance.

We may experience defects and system failures with respect to our technology, which would harm our business and reputation and expose us to potential liability. Our service is based on sophisticated software and hardware systems, and we may encounter delays when developing or implementing new technological solutions or service enhancements. Further, the technology solutions underlying our service may in the future contain undetected errors or defects when first introduced or when new versions are released. In addition, we may experience difficulties in installing or integrating our technologies on various software platforms. Defects in our technology solutions, errors or delays in development of our technology and service, or other difficulties could result in the interruption of business operations, a delay in market acceptance of our service, additional development and remediation costs, diversion of technical and other resources, or a loss of customers.

The Company’s cash position is relatively weak. The Company currently has limited cash balances. The Company could be harmed if it is unable to meet its cash demands, and the Company may not be able to continue operations if they are not able to raise additional funds.

The Company may require additional financing to support working capital needs. The Company may need to explore additional financing transactions that management determines are in the best interest of the Company, including, without limitation, commercial debt transactions, private offerings of debt or equity securities, and other strategic alternatives. Such additional financing may not be available to the Company, or, if available, the Company may be unable to undertake such additional financing on terms that are advantageous to the Company. If the Company fails to raise additional capital in such an offering, or through other fund rising efforts, such a failure could have a material adverse effect on the Company, and investors in this Offering could be at greater risk of losing their investments due to the inability of the business to proceed with enough working capital to effectively run the Company.

If the Company incurs commercial debt, there may be risks associated with such borrowing. If the Company incurs commercial indebtedness, a portion of its cash flow will have to be dedicated to the payment of principal and interest on such indebtedness. Typical loan agreements also might contain restrictive covenants, which may impair the Company’s operating flexibility. Such loan agreements would also provide for default under certain circumstances, such as failure to meet certain financial covenants. A default under a loan agreement could result in the loan becoming immediately due and payable and, if unpaid, a judgment in favor of such lender which would be senior to the rights of shareholders of the Company. A judgment creditor would have the right to foreclose on any of the Company’s assets resulting in a material adverse effect on the Company’s business, operating results or financial condition.

Management has broad discretion as to the use of proceeds. The net proceeds from this offering will be used for the purposes described under “Use of Proceeds.” The Company reserves the right to use the funds obtained from this Offering and the Debt Offering for other similar purposes not presently contemplated, which it deems to be in the best interests of the Company in order to address changed circumstances or opportunities. This poses a risk to an investor should they be relying on current use of proceed forecasts for the investment as business conditions may require a change of the use of these funds.

The Company has not prepared any audited financial statements. Therefore, investors have no audited financial information regarding the Company’s capitalization or assets or liabilities on which to make investment decisions. If investors feel the information provided is insufficient, then they should not invest in the Company.

Management has voting control of the Company. Management of the Company presently holds a majority of the issued and outstanding voting common stock in the Company. Due to their stock ownership and positions with the Company, the current officers will be in a position to continue to control the affairs and management of the Company after the Offering. Investors must rely entirely on our management to govern the affairs of the Company.

The Company must file a Form D for its Regulation D offering, as separate from this Offering. The SEC rules require a Form D to be filed by companies within 15 days after the first sale of securities in the offering relying on Regulation D. Failing to register with the SEC or get an exemption may lead to fines, the right of investors to get their investments back, and even criminal charges. There is a risk that a late penalty could apply should the Company be late in its filing.

The outbreak of the novel coronavirus, COVID-19, has adversely impacted global commercial activity and contributed to significant declines and volatility in financial markets. The coronavirus pandemic and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. The rapid development and fluidity of this situation precludes any prediction as to the ultimate material adverse impact of the novel coronavirus. Nevertheless, the novel coronavirus presents material uncertainty and risk with respect to the Funds, their performance, and their financial results.

There may be unanticipated obstacles to the execution of the Company’s business plan. The Company’s business plan may change significantly. Our business plan is capital intensive. We believe that our chosen activities and strategies are achievable in light of current economic and legal conditions with the skills, background, and knowledge of our principals and advisors. Our management reserves the right to make significant modifications to its stated strategies depending on future events. Investors must be prepared for these potential modifications to stated strategies and understand the inherent risk to their investment that these modifications could pose.

Other economic and public health conditions in the markets pose risks. We are subject to risks including rising operational costs, labor costs, increased transportation costs, natural disasters, terrorist attacks, outbreaks of public health pandemics or other diseases, or any third-party conduct which could negatively impact our business. Various economic and public health conditions can have a significant negative impact on our business. Economic conditions may also be negatively impacted by terrorist attacks, wars and other conflicts or the prospect of such events. Any weakened economic and business climate, as well as consumer uncertainty created by such a climate, could harm our revenues and profitability. In addition, during times of economic difficulty, in an effort to maintain sales during such times we may need to reduce the price of our service, increase our promotional spending, or take other steps to encourage consumer purchases of our service. Those steps may lower our net revenues, if any, decrease our operating margins, increase our costs and/or lower our profitability, to the extent it is ever achieved.

Risks Associated with an Investment in Securities Best efforts offering. This Offering is being made on a “best efforts” basis. As subscriptions are accepted (and any required rescission periods expire), subscriptions are irrevocable and subscribers will not have the opportunity to have their funds returned notwithstanding any future lack of success in recruiting other investors. Accordingly, initial subscribers will necessarily have a greater degree of risk. The Company has not engaged the services of an underwriter with respect to this offering, and there is no guarantee that any number of shares of common stock are sold and proceeds will be realized by the Company.

An investment in the Company’s securities involves substantial risk. Prospective investors should consider carefully the factors referred to below as well as others associated with their investment. In addition, this offering contains forward-looking statements regarding future events and the future financial performance of the Company that involve significant risks and uncertainties. Investors are cautioned that such statements are predictions and beliefs of the Company, and the Company's actual results may differ materially from those discussed herein. The discussion below includes some of the material risk factors that could cause future results to differ from those described or implied in the forward-looking statements and other information appearing elsewhere herein.

The Offering price is arbitrary. The price of the Shares offered has been arbitrarily established by the Company, without considering such matters as the state of the Company’s business development and the general condition of the industry in which it operates. The price of the shares bears little relationship to the assets, net worth, or any other objective criteria of value applicable to the Company.

Shares are not guaranteed and could become worthless. The shares to be issued under this offering are not guaranteed or insured by any government agency or by any private party. The amount of earnings is not guaranteed and can vary with market conditions. The return of all or any portion of capital invested in the shares is not guaranteed, and the shares could become worthless.

Future capital needs; Dilution. The Company believes that the net proceeds of the offering will be sufficient to fund the implementation of the Company’s business plan, operations and growth for the foreseeable future, assuming that it sells all shares offered hereby and that the revenue forecasts for the first 12 months are substantially achieved. Nevertheless, in the event that additional capital is required, no assurance can be given that additional financing will be available at all or on terms favorable to the Company. If adequate funds were not available to satisfy either short or long-term capital requirements, the Company may be unable to continue in business, with a resulting loss of all or part of investments made by the Company’s investors. Moreover, if additional equity securities are issued in connection with future financings, the ownership percentages of then shareholders could be diluted. Dilution of ownership percentages may also occur as a result of equity securities issued pursuant to possible sales or grants to existing shareholders, officers, managers, consultants, advisors, and/or employees.

We are relying on certain exemptions from registration. The shares are being offered for sale in reliance upon certain exemptions from the registration requirements of the Securities Act and applicable state securities laws. If the sale of the shares were to fail to qualify for these exemptions, purchasers may seek rescission of their purchases of the shares. If a number of purchasers were to obtain rescission, the Company would face significant financial demands, which could adversely affect the Company as a whole, as well as any non-rescinding purchasers.

The Shares are restricted securities and a market for such securities may never develop. Investors should be aware of the potentially long-term nature of their investment. Each purchaser of shares will be required to represent that it is purchasing such securities for its own account for investment purposes and not with a view to resale or distribution. Purchasers may be required to bear the economic risks of the investment for an indefinite period of time. The Company has neither registered the shares, nor any other securities under the Securities Act. Consequently, shareholders may not be able to sell or transfer their securities under applicable federal and state securities laws. Moreover, there is no public market for the Company’s securities, such a market is not likely to develop prior to a registration undertaken by the Company for the public offering of its securities for its own account or the account of others, and there can be no assurance that the Company will ever have such a public offering of its securities. Ultimately, each investor’s risk with respect to this Offering includes the potential for a complete loss of his or her investment.

The Common Stock will not be freely tradable until one year from the initial purchase date. Although they may be tradable under federal securities law, state securities regulations may apply and each Purchaser should consult with his or her attorney. You should be aware of the long-term nature of this investment. There is not now, and there may not be, a public market for the common stock. Because the Common Stock has not been registered under the 1933 Act or under the securities laws of any state or non-United States jurisdiction, the Common Stock has transfer restrictions under Rule 501 of Regulation CF. It is not currently contemplated that registration under the 1933 Act or other securities laws will be affected. Limitations on the transfer of the Common Stock may also adversely affect the price that you might be able to obtain for them in a private sale. Purchasers should be aware of the long-term nature of their investment in the Company. Each Purchaser in this Offering will be required to represent that it is purchasing the Securities for its own account, for investment purposes, and not with a view to resale or distribute thereof.

We may be required to register under the Securities Exchange Act. The Company will be required to conform to the rules and regulations promulgated under the various federal and state securities laws applicable to the conduct of its business. Management does not believe that the Company’s activities, as presently contemplated, will require registration or qualification of the Company with any federal or state agency.

Although the Company does not intend to be required to register its securities under the Securities Exchange Act of 1934, as amended, it is possible that the Securities and Exchange Commission (the “SEC”) may require the Company to so register. For example, under Section 12(g)(1) of the Securities Exchange Act (as amended by the JOBS Act of 2012), private companies with over 2,000 shareholders and over $10,000,000 in assets, may be required to register with the SEC within 120 days after their fiscal year end. Such registration would increase the operational expenses of the Company and would restrict its activities, thereby possibly having an adverse effect on its business.

The Sarbanes-Oxley Act of 2002 could, should the Company take such action, make the Company’s entrance into the public market difficult and expensive. In the wake of well-publicized corporate scandals associated with Enron and WorldCom involving management self-dealing and accounting fraud, in July 2002, President Bush signed into law the Sarbanes-Oxley Act of 2002. The Sarbanes-Oxley Act—the most far reaching legislation affecting the federal securities laws since they were created in the 1930’s—impacts everything from the role of auditors to public reporting of stock trades by management, from committee independence to reporting of off-balance sheet transactions, and from officer loans to employee whistle-blowing.

Public and registered companies are facing dramatic changes in disclosure and corporate governance requirements under the Sarbanes-Oxley Act, and under new and proposed rules from the SEC, NASDAQ and the NYSE. While these new rules and regulations do not generally cover private companies, their influence on private companies is being felt in the following ways:

  • A private company will become subject to the Sarbanes-Oxley Act upon filing a registration statement with the SEC in anticipation of an IPO.
  • The Sarbanes-Oxley Act may result in increased scrutiny of a private company being considered for acquisition by a public company.
  • In order to conduct an IPO, a private company would need to evaluate its organization against the requirements of the Sarbanes-Oxley Act and develop a compliance program.
  • Full compliance with the Sarbanes-Oxley Act – which can be time-consuming and expensive – can significantly slow the efforts of private companies such as the Company that may seek to enter the public markets.

You may have limited rights. The Company may not have yet authorized preferred stock, and there is no way to know what voting rights those securities will have in the future. In addition, as an investor in the Regulation CF offering, you will be considered a Non-Major Investor (as defined below) under the terms of the notes offered, and therefore, you have more limited information rights.

View our
Offering Documents


Meet the Kiddie, Inc. team

Alberto Prieto

International Entrepreneur & Business Manager / Industry Digital Transformation Advocate / Customer Happiness & Success Champion

Co-Founder of KiddieRX
Lee Lefkowitz

Multiple Business Investor and Co-Founder / Accountant / PR & Engagement Specialist

Co-Founder of KiddieRX
Diane Israel

International Private Banker / Co-Founder

Chief Legal Officer
Jonathan Jaffe

Represented Publicly Traded Companies / Litigation and Transactional Support / Associate, Nation Lawyers Chartered

Press Mentions





Legal Counsel:

Nations Lawyers Chartered

10251 W. Oakland Park Blvd.

Sunrise, FL 33351

Office: (954) 280-2000



”Missing work and driving in traffic has been a nightmare for pediatrician visits for my son. Now, I will not have to worry about that anymore.”

Wagner M.


”As a father of two girls, having an app available from the comfort of our home for a doctor visit is amazing.”

Steve D.


”Having young kids at home and not worrying about having to leave home to visit the pediatrician is a great idea. I should have thought of this myself.”

Michele L.

Project FAQs

Ask A Question